NEUROCRINE BIOSCIENCES, INC for NEUROCRINE BIOSCIENCES, INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 20, 2020 | $440,000 | Replaced |
| 2nd Quarter - Amendment | Jul 20, 2020 | $440,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
H.R. 3 Elijah E. Cummings Lower Drug Costs Now Act. S.2543 Prescription Drug Pricing Reduction Act of 2019. Structure and reimbursement for Medicare Part D. Access to and reimbursement for telemedicine.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID BOYER | Sp. Ast. Pres LA, Ast Com Leg, FDA; Sp Ast Sec HHS, Con Asst, Off of WH Liaison DOD, Con Asst, Off of Sec Lab. |
| TIMOTHY CLARK | — |
Health Issues HCR
Regulatory and legislative health care issues impacting pricing and access; Diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinsons Disease
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.